Trial of Quercetin in the Treatment and Prevention of Chemotherapy-induced Neuropathic Pain in Cancer Patients
NCT ID: NCT02989129
Last Updated: 2018-04-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
EARLY_PHASE1
INTERVENTIONAL
2018-04-30
2020-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer
NCT00112996
UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants
NCT00098969
Cannabidiol for Prevention of Chemotherapy-induced Peripheral Neuropathy
NCT04582591
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients
NCT00659269
L-Carnitine L-Tartrate in Preventing Peripheral Neuropathy Caused By Chemotherapy in Women With Metastatic Breast Cancer
NCT00754767
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
If participant is found to be eligible to take part in this study, participant will take quercetin tablets by mouth 2 times every day for 12 weeks. The study staff will give participant the tablets and additional instructions on how to take the study product.
Length of Participation:
Participant may take quercetin for up to 12 weeks. Participant will no longer be able to take quercetin if the pain symptoms gets worse, if intolerable side effects occur, or if participant is unable to follow study directions.
Study Visits:
Every week, participant will either come to the clinic or a member of the staff will call participant to learn how participant is doing, if participant has had any side effects, and to check that participant is taking quercetin correctly. Participant will also complete a questionnaire about any pain symptoms participant may be having. The call/questionnaire should take about 10-15 minutes to complete.
End-of-Study Visit:
About 7 days after participant's last dose of quercetin, participant will complete the same questionnaires participant completed at screening.
Participation in this study will be over after the end-of-study visit.
This is an investigational study. Quercetin is commercially available as a supplement, but it is not FDA approved.The study doctor can explain how the study product is designed to work.
Up to 20 participants will be enrolled in this study. All will take part at MD Anderson.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chemotherapy Induced Neuropathic Pain (CINP) Treatment Group
Questionnaires completed at Baseline and at End of Study Visit.
Participants take Quercetin tablets by mouth 2 times every day for 12 weeks.
Questionnaires
Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.
Quercetin
500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
Chemotherapy Induced Neuropathic Pain (CINP) Prevention Group
Questionnaires completed at Baseline and at End of Study Visit.
Participants take Quercetin tablets by mouth 2 times every day for 12 weeks.
Questionnaires
Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.
Quercetin
500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Questionnaires
Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.
Quercetin
500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients starting, undergoing or completed chemotherapy at MD Anderson Cancer Center
3. Any cancer patients who received any of the chemotherapeutic agents listed below and developed neuropathic pain for the treatment cohort; or any cancer patients who have been scheduled to receive any of the chemotherapeutic agents listed below for the preventive cohort. The chemotherapeutic agents include 1) taxanes (paclitaxel, docetaxel), 2) vinca alkaloids (vincristine, vinblastine), 3) platinum agents (cisplatin, carboplatin, oxaliplatin), and 4) others (thalidomide, bortezomib, lenalidomide).
4. Patients have neuropathic pain intensity of at least 4/10 on numeric rating score (NRS, 0/10 being no pain and 10/10 excruciating pain) for the treatment cohort; or 0/10 on NRS for the preventive cohort.
5. Patients are on stable dose of any medication
6. Patients followed at the Pain Medicine department. Patients with normal renal function (Normal values, BUN (blood urea nitrogen): 8 to 20 mg/dL, Creatinine: 0.7 to 1.3 mg/dL).
7. Patients able to speak English.
8. Patients able to review, understand, and provide written consent.
9. Patients with an Eastern Cooperative Oncology performance (ECOG) status of 0-2.
Exclusion Criteria
2. Pregnancy.
3. Hypersensitivity reaction, anaphylaxis, or any other serious adverse reaction to quercetin or product components.
4. Patients who are enrolled in another Pain Medicine trial.
5. Patients with malabsorption syndrome or resection of the stomach or small bowel.
6. Patients with any condition that precludes use of the study medication as determined by the treating physician.
7. Patients taking Quercetin for other medical reasons.
8. Patients taking Digoxin.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
M.D. Anderson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Salahadin Abdi, MD, PHD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Related Links
Access external resources that provide additional context or updates about the study.
University of Texas MD Anderson Cancer Center Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016-0287
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.